February 2025 in “Expert Opinion on Drug Safety” This study analyzed adverse event reports from the FDA Adverse Event Reporting System and identified new side effects of topical minoxidil, such as application site acne and cysts, which are not well-documented on product labels, suggesting a need for updated safety information.
February 2025 in “Journal of Dermatological Treatment” The study explores the potential effectiveness of low-dose oral minoxidil in treating short anagen hair syndrome, suggesting it may be a viable treatment option despite the condition often resolving spontaneously with puberty.
January 2025 in “Anais Brasileiros de Dermatologia” This review examines male androgenetic alopecia and reports no new clinical results, offering insights to aid dermatologists in making informed therapeutic decisions.
In this randomized, controlled trial, the researchers observed that sub-lingual minoxidil at doses of 1.35 mg and 4.05 mg, but not 0.45 mg, significantly increased hair fibre diameter in men with male androgenetic alopecia over 24 weeks, suggesting a dose-dependent reversal of follicle miniaturization.
January 2025 in “Journal of Drugs in Dermatology” This study found that oral minoxidil is superior to topical minoxidil in terms of ease of use, adherence, and patient satisfaction, without increasing systemic side effects, although it did have a higher incidence of hypertrichosis.
March 2024 in “JAAD International” This review discusses the potential strategy of continuing topical minoxidil when starting low dose oral minoxidil to mitigate initial hair shedding in alopecia, but reports no new clinical results.
August 2023 in “Journal of Cosmetic Dermatology” This study characterized the activity of naturally occurring minoxidil sulfotransferase enzymes in various plants and found that seven out of ten botanical extracts showed significant activity, suggesting these could potentially enhance minoxidil response in treating androgenetic alopecia.
This review discusses the genetic differences between male and female pattern hair loss and highlights the uncertainty surrounding genetic factors in female pattern hair loss, but reports no clinical results.
This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
May 2023 in “International Journal of Trichology” In this study, 70% of female androgenetic alopecia patients who did not respond to standard minoxidil experienced clinical improvement after switching to a propylene glycol-free, witch hazel-based 5% minoxidil sulfate solution, with the treatment also being well-tolerated.
April 2023 in “Dermatology and therapy” This study found a high discontinuation rate of topical minoxidil among patients with androgenetic alopecia, largely influenced by short treatment duration, lack of efficacy, and adverse effects.
16 citations
,
June 2021 in “Journal of Dermatological Treatment” This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.
1 citations
,
June 2021 in “Journal of Cosmetic Dermatology” In this study, the addition of a SULT1A1 enzyme booster to daily 5% minoxidil treatment significantly increased hair regrowth in men with androgenic alopecia compared to minoxidil alone.
178 citations
,
April 2017 in “Journal of The American Academy of Dermatology” This systematic review and meta-analysis found that minoxidil, finasteride, and low-level laser light therapy significantly improve hair growth in men with androgenetic alopecia, while minoxidil is also effective for women, compared to placebo.
20 citations
,
April 2014 in “Dermatologic Therapy” This study reported that sulfotransferase activity in plucked hair follicles can predict treatment response to 5% topical minoxidil in women with androgenetic alopecia with high sensitivity and specificity.
3 citations
,
May 2013 in “Journal of the American Association of Nurse Practitioners” This review evaluates six primary studies on androgenetic alopecia treatments and suggests topical minoxidil or finasteride as first-line options, recommending further research into treatments and practice guidelines.
29 citations
,
November 2012 in “Journal of The European Academy of Dermatology and Venereology” This review discusses the development of an algorithmic guideline for treating androgenetic alopecia in Asian patients, using the BASP classification to address limitations of previous guidelines, and reports no clinical results.
198 citations
,
October 2011 in “Journal der Deutschen Dermatologischen Gesellschaft” This article discusses the development of an evidence-based guideline for treating androgenetic alopecia and reports no new research results.
88 citations
,
February 2011 in “Journal of Dermatological Science” This study found that topical minoxidil modestly extended the anagen phase in mice by activating β-catenin activity in dermal papilla cells.
122 citations
,
November 2010 in “Journal of Dermatological Science” This study found that increased expression of type II 5α-reductase, androgen receptors, and Hic-5/ARA55 in dermal papilla cells upregulates androgen sensitivity, playing a key role in androgenetic alopecia pathogenesis.
125 citations
,
May 2007 in “Journal of The American Academy of Dermatology” This study describes the development of the BASP classification system, providing a universal and systematic approach for classifying pattern hair loss in both men and women.
269 citations
,
August 2002 in “Journal of The American Academy of Dermatology” This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.
116 citations
,
September 2001 in “Journal of The American Academy of Dermatology” This study suggests that miniaturization in pattern hair loss may occur abruptly and can be reversed with treatment, as supported by histologic evidence in finasteride-responsive patients.
192 citations
,
March 1998 in “British Journal of Dermatology” This study found that minoxidil significantly increases VEGF mRNA and protein expression in dermal papilla cells, suggesting a role in enhancing hair follicle vascularization in androgenetic alopecia.
139 citations
,
July 1991 in “Journal of The American Academy of Dermatology” This article discusses the structure of hair follicles and their significance in evaluating hair disorders, but it does not report any new research findings.
67 citations
,
March 1987 in “Journal of The American Academy of Dermatology” This study found that both 2% and 3% minoxidil resulted in a significant increase in hair counts for participants with androgenetic alopecia over 12 months.
